文献速递病毒性肝炎

慢性丁型肝炎患者的干扰素治疗疗程及其对疾病自然病程的影响

Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease.
PubMed 文献 · J Infect Dis · 2018-01-01

基于333例慢性丁型肝炎患者数据库,分析其中99例接受至少6个月干扰素治疗者,中位累积疗程24个月,中位随访55个月。35例获得维持病毒学应答,应答率随疗程延长而增加,5年时达50%。获得维持病毒学应答者肝病死亡或并发症风险低于无应答者,基线肝硬化与无应答预测不良终点。

要点

  • 干扰素是慢性丁型肝炎唯一治疗选择,病毒学应答随疗程延长而增加。
  • 维持病毒学应答者5年累积概率达50%,肝病死亡或并发症风险低于无应答者。
  • 基线肝硬化与无应答预测不良终点,疗程需个体化并仔细评估治疗后反应。

核心结论

  • 干扰素病毒学应答随治疗疗程延长而增加,并有利影响疾病自然病程。
  • 干扰素治疗疗程必须个体化,并进行仔细的治疗后评估。

研究设计与样本

  • 分析慢性丁型肝炎数据库(333例患者,其中161例有干扰素治疗史)。
  • 选取99例接受至少6个月干扰素治疗的慢性丁型肝炎患者。

主要发现

  • 35例患者获得维持病毒学应答(定义为治疗停止后丁型肝炎病毒RNA阴性持续2年)。
  • 累积中位干扰素疗程为24个月(范围6-126个月),中位疗程数2个(范围1-8)。
  • 治疗后中位随访55个月(范围24-225个月)。
  • 维持病毒学应答的累积概率随疗程延长而增加,5年时达到50%。
  • 与未获得维持病毒学应答者相比,获得维持病毒学应答者死于肝病或发生并发症的可能性更低(P=0.032,P=0.006)。

关键数值与推荐

  • 维持病毒学应答定义为治疗停止后丁型肝炎病毒RNA阴性持续2年。
  • 基线肝硬化预测不良终点的比值比为16.1,对治疗无应答预测不良终点的比值比为5.23。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interferon is the only treatment option in chronic delta hepatitis (CDH). A CDH database (333 patients, 161 with interferon treatment history) was analyzed for effects of treatment duration on virologic response and clinical outcomes. METHODS: Ninety-nine CDH patients who received at least 6 months of interferon were selected. Maintained virologic response (MVR) was defined as hepatitis D virus RNA negative for 2 years after treatment discontinuation. Cumulative median interferon treatment duration was 24 months (range 6-126 months), with a median of 2 courses (range 1-8). Post-treatment median follow-up was 55 months (24-225 months). RESULTS: Thirty-five patients achieved MVR. Cumulative probability of MVR increased with treatment duration and reached 50% at 5 years. Patients with MVR were less likely to die from liver disease or develop complications compared to patients without MVR (P = .032, P = .006, respectively). Cirrhosis at baseline and no response to therapy (odds ratio 16.1 and 5.23, respectively) predicted an adverse endpoint. Hepatitis B surface antigen clearance occurred in 37% of patients with MVR. CONCLUSION: Viral response to interferon increases with treatment duration and favorably affects the natural course of disease. Interferon treatment duration has to be individualized with careful post-treatment assessment.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yurdaydin C, Keskin O, Kalkan Ç, et al. Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. J Infect Dis. 2018. PMID: 29425306. doi:10.1093/infdis/jix656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。